	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
Name of Company:	Financial Services Consumer Panel	
Disclosure of comments:	EIOPA will make all comments available on its website, except where respondents specifically request that their comments remain confidential.	Public
	Please indicate if your comments on this CP should be treated as confidential, by deleting the word Public in the column to the right and by inserting the word Confidential.	
	Please follow the following instructions for filling in the template:	
	Do not change the numbering in the column "reference"; if you change numbering, your comment cannot be processed by our IT tool	
	\Rightarrow Leave the last column <u>empty</u> .	
	Please fill in your comment in the relevant row. If you have <u>no comment</u> on a paragraph or a cell, keep the row <u>empty</u> .	
	⇒ Our IT tool does not allow processing of comments which do not refer to the specific numbers below.	
	Please send the completed template, <u>in Word Format</u> , to <u>CP-16-006@eiopa.europa.eu</u> .	
	Our IT tool does not allow processing of any other formats.	
	The numbering of the questions refers to the Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	
Reference	Comment	
General Comment	The Financial Services Consumer Panel is an independent statutory body, set up to represent the interests of consumers in the development of policy for the regulation of financial services in the UK.	
	The Panel welcomes this opportunity to comment on EIOPA's proposed Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	

	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
	(IDD).	
	The Panel is broadly supportive of the proposed draft Technical Advice. The proposals are detailed and far-reaching and generally introduce enhanced rules for the protection of consumers, in line with the objectives of the IDD.	
Question 1		
Question 2	The Panel broadly agrees that the proposals provide a sufficient level of detail. However, as previously argued, we believe that EIOPA should consider urging companies to make their Product Oversight and Governance (POG) arrangements public to allow for greater scrutiny. In addition to increasing transparency, this would ensure rules put in place are more than a simple box-ticking exercise and it would encourage consumer confidence.We remain concerned that EIOPA still appears content for the periodic review as currently foreseen to be conducted entirely internally within each firm. Reviewing POG arrangements independently could mean shortcomings are flagged up promptly. For example, the review could be covered by a firm's Audit Committee report, and thus be overseen by its auditors.	
Question 3		
Question 4		
Question 5		
Question 6		
Question 7	The draft Technical Advice on target market refers to the need to check compatibility of the product with certain types of customers and introduces a level of granularity in identifying a specific target market that we welcome. We agree it is essential that manufacturers are compelled to identify a target market in the development stage and to only add features that meet the needs of the target market. Too often, miss-selling of financial products is driven by the need to sell high volumes – irrespective of whether the product meets the individual clients' needs.	

	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
	However, there is also an argument that some basic products can be appropriate for a large and diverse target market. The Panel has previously argued that more work needs to be done in establishing a test for whether a product can be deemed simple or not, as part of identifying the target market. Manufacturers and distributors should in particular consider the design and marketing of simple products that can be readily understood by all consumers.	
	We would like to reiterate the findings of the 2013 UK's Sergeant Review of Simple Financial Products (https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/1917 21/sergeant_review_simple_products_final_report.pdf), which found that many consumers need simple financial products because of "the challenge of making good choices in what seems to many to be an overwhelmingly complicated marketplace with a very wide range of products which are complex and difficult to understand".	
	The review also established a set of principles, which form the basis of an objective test to establish whether a product is simple or not. These include for example the use of standardised language, a transparent fee structure and straightforward and clear purchasing process.	
	We would encourage EIOPA, in cooperation with the other ESAs, to conduct a similar exercise at EU-level to establish such operating principles for manufacturers. To ensure adequate consumer understanding of the types of products they are offered, it is also critical that a designation of a product as 'simple' is subject to oversight by a regulator or another independent body.	
Question 8	Whilst the Panel agrees with the proposed review obligations for both manufacturers and distributors we do believe that there should be a minimum frequency of reviews imposed by EIOPA. The Panel would like to propose that complex products such as insurance-based investment products have a review period of only one year and less complex non-life or pure life products, three years.	

	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
	We were disappointed by the recommendation that if an event materially affecting the potential guarantees to the identified target market occurs, action will be decided upon on a case-by-case basis. We would have preferred EIOPA to stipulate the regulatory action/actions that could be taken in the case of an event occurring. That said, we welcome the non-exhaustive list provided of possible actions that could be taken which manufacturers (and distributors if relevant) should find helpful. We also welcome the proposal that the senior management body and/or the compliance function of the manufacturer or distributor should have responsibility for the oversight of the product governance process as this clearly states where the responsibility for good governance lies.	
Question 9	 The Panel strongly believes that the emphasis should be on the avoidance and elimination of conflicts, rather than their 'management' and therefore welcome EIOPA's recommendation that manufacturers and distributors put in place a robust conflict of interest policy which is regularly reviewed. We agree that disclosure of conflict of interests, whilst essential if such a conflict should occur, should be a step of last resort and that overreliance on disclosure should be considered a deficiency in the conflicts of interest are a crucial factor in many instances of miss-selling, and manufacturers and distributors should be called on to eliminate them wherever possible. We also welcome the inclusion of examples of situations where conflicts of interest shall be assumed until otherwise eliminated. 	
Question 10		
Question 11	The Panel strongly agrees with this high level principle. Unfair and excessive	

	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
	inducements have proved to be the reason for miss-selling and a cause of great detriment for consumers.	
	We also welcome the inclusion of a non-exhaustive list of examples where an inducement may generally be regarded as having a detrimental effect on the quality of the service to the customer. Examples can aid with clarity if manufacturers or distributors are unclear.	
Question 12	The Panel would support the inclusion of internal remuneration packages. The Panel would urge EIOPA to consider a review of internal remuneration packages as excessive bonus payments or a requirement to produce high volume sales in order to meet minimum salary payments is also a cause of miss-selling.	
	The Panel would also like to point out the need for clarification on the definition of inducements as presently outlined in the consultation document. In its Draft Technical Advice EIOPA has interpreted the term " <i>inducement"</i> to mean "() any fee, commission or non-monetary benefit () paid to or by any party except the customer or a person on behalf of the customer". However, in the preceding analysis, it considers an inducement to be "in relation to fees or commissions as well as non-monetary benefits paid by or to third parties only" which would exclude those payments which do not originate from a third party (rather than only excluding just those originating from the customer as per the former).	
Question 13		
Question 14		
Question 15	The Panel agrees with the high level criteria used. There is no criteria we would suggest excluding.	
Question 16	The Panel agrees that insurance specificities should be reflected in the policy proposals. However, we note that Policy Option 2 (Preferred Option) whilst offering a reasonable 'middle ground' may not capture all the elements required to assess whether an insurance-based investment is a suitable product for a consumer.	

	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
	Investments which also have an insurance element will have additional costs which will affect the performance of the investment (as any cost or charge applied against a product must). Insurance-based investment products (IBIPs) serve two needs: one for protection and one for investment. Bundling these two very different requirements together may not always be the most efficient or cost effective method of providing either. Therefore it is essential that the manufacturer or the distributor fully reflects why an IBIP is the most suitable product for both the investment and protection needs and why this cannot be replicated elsewhere through two separate products. Policy Option 3 on the other hand has a requirement for substantially different types of information to be obtained from the customer in order to fully take into account the customer's "basic needs" and certain insurance-specific elements of an IBIP (such as biometric risk cover). Given that the costs and charges associated with IBIPs are higher and that the need for both investment and protection is likely to be less prevalent with many consumers, the Panel favours Option 3.	
Question 17	 The consultation document provides good guidance on the information that would be required in order for suitability and appropriateness to be fully assessed. Specifically, the following information should be included in addition to demands and needs: Details of the customer's current income and expenditure and any expectations of future changes; Breakdown of customer's assets and other financial products, including protection products and employment benefits, if applicable; Family circumstances, including any dependencies; The customer's risk profile. Their appetite for risk, but more importantly their capacity for loss. So how much can they realistically afford to lose? The customer's savings and investment objectives, including how long the 	

	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
	investment will be held and their retirement plans.	
Question 18	The Panel believes this would be useful. It is essential that crucial information is collected so that suitability and appropriateness can be adequately assessed and then applied against the established demands and needs of the customer. However, there is likely to be overlap in the collection of information and data to comply with these two statutory requirements.	
	Some manufacturers/distributors may be better equipped than others to collect this data in a streamlined fashion which won't over burden the customer. Others may be over compliant, concerned only with the regulatory consequences of 'getting it wrong'. Nor should the collection of data be reduced to a tick-box exercise. Therefore, we feel guidance and some prescription is needed here to help intermediaries and firms get this right.	
	The process for collecting data to satisfy both the suitability and appropriateness requirements and the demands and needs test should be personal and on a one-to-one basis with the customer. It is essential that the customer understands why these questions are being asked and the importance of answering them fully and honestly – and the consequences should they provide inadequate answers or `guessing'.	
	We feel that EIOPA could provide valuable guidance which all manufacturers and distributors could follow when collecting information from customers to meet both of these statutory requirements. More importantly, this would ensure that the necessary data is being collected in order for a full suitability assessment to be made against the customer's demands and needs.	
Question 19	The Panel broadly agrees with the high level and cumulative list of criteria used to define other non-complex products. There is no criteria we would suggest making optional or any we would exclude.	
	However, we do have concerns that the perception of what is, in truth, a non-complex product or a complex product, depends very much on the knowledge and experience	

	Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
	of the purchaser. Our concern is that even relatively simple investment-based products might appear complex to the inexperienced investor, but if sold without advice, there may be no requirement to establish suitability or appropriateness.	
Question 20		
Question 21		
Question 22	We agree with the high level criteria used. There are no criteria we would exclude.	
Question 23	Yes.	
Question 24	The Panel agrees with the high level criteria used with regard to the suitability statement and periodic communications to customers. There are no criteria we would wish to see excluded.	
	However, the Panel believes the suitability statement should highlight any needs identified that are not met by the recommended product. Many consumers may not, unprompted, identify all their needs but during the data collection phase further needs may be uncovered that the customer does not wish to have addressed at that time. We believe these should be noted and the suitability statement is a good document to use for this purpose.	
	If it is decided that a periodic review shall take place, the fact that needs not met by the original recommendation are contained in the suitability statement will act as a prompt for both the customer and the intermediary during the review.	
Question 25	Yes.	
Question 26	See response to Question 24 concerning any needs not met by the original recommendation. It would also be useful if the periodic communication could highlight if a more suitable product or solution has been introduced since the first recommendation was made.	

Comments Template on Consultation Paper on Technical Advice on possible delegated acts concerning the Insurance Distribution Directive	Deadline 3 October 2016 18:00 CET
In addition, it would be helpful if the total cost paid into the policy could be published alongside the current surrender value, so the customer can easily identify the actual performance of the investment to date. Often only premiums paid during the last year are shown which does not provide a complete picture.	